[Expression of adhesion molecules on CD34+ cells of BM and PB stem cell samples during high-dose chemotherapy combined with transplantation of autologous PB stem cells].
This study was aimed to investigate the expressions of adhesion molecules such as CD54, CD49d and CD62L by CD34(+) cells sampled from different stages of bone marrow (BM) and peripheral blood (PB) before/after G-CSF mobilization and after transplantation through the direct labeling with three colour-immunofluorescence and flow cytometry, and to explore the differences in expression of adhesion molecules on CD34(+) cells from different origins and their clinical significance. Mononuclear cells collected from BM and PB before mobilization, after collection of stem cells and hematopoietic recostruction of BM at the end of transplantation were marked with CD54-FITC, CD49d-FITC and CD62L-FITC separately, as well as CD34-PE and CD45PerCE. 3-color fluorescene analysis was carried out by FACS. The expression differences of CD34(+) and adhesion molecules between BM and APBSC were compared. The results showed that expression differences of CD54, CD49d and cd62Lon CD34(+) cells belore mobilization, after collection and reconstraction of transplantation were not statiscally significant, the difference of CD54, CD49d and CD62L on CD34(+) between 1st and 2nd collections of hematopoietic stem cells also were not statiscally significant. In the collected APBSC, the expression level of CD34(+) CD49d(+) was significantly lower than those in BM before mobilization (P = 0.001). It is concluded that the method of chemotherapy combined with G-CSF mobilization can down-regulate CD49d expression in BM CD34(+) cells, thus can mobilize and move theirs into peripheral blood. After the reconstitution by transplantation, the expression of CD49d on CD34(+) cells tends to normal, the clinical significance needs to be elucidated by accumulation of much more cases.
Liu
Peng
P
Department of Internal Medicine, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, 100021 China.
Han
Xiao-Hong
XH
Shi
Yuan-Kai
YK
He
Xiao-Hui
XH
Yang
Cheng
C
Ai
Bin
B
D000293:Adolescent; D000328:Adult; D015703:Antigens, CD / Q000097:blood; D018952:Antigens, CD34 / Q000097:blood*; D000951:Antigens, Neoplasm / Q000097:blood; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001854:Bone Marrow Cells / Q000276:immunology*; D000074301:CD52 Antigen; D015815:Cell Adhesion Molecules / Q000097:blood*; D003131:Combined Modality Therapy; D005260:Female; D005434:Flow Cytometry; D006023:Glycoproteins / Q000097:blood; D006412:Hematopoietic Stem Cells / Q000276:immunology; D006801:Humans; D039441:Integrin alpha4 / Q000097:blood; D019041:L-Selectin / Q000097:blood; D007963:Leukocytes, Mononuclear / Q000276:immunology; D008223:Lymphoma / Q000097:blood / Q000276:immunology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D036102:Peripheral Blood Stem Cell Transplantation / Q000379:methods*; D014182:Transplantation, Autologous
D015703:Antigens, CD; D018952:Antigens, CD34; D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents; D000074301:CD52 Antigen; C000613862:CD52 protein, human; D015815:Cell Adhesion Molecules; D006023:Glycoproteins; D019041:L-Selectin; D039441:Integrin alpha4